Evaluation of a novel real-time fluorescent polymerase chain reaction assay for high-risk human papilloma virus DNA 
genotypes in cytological cervical screening

Cheng,Jiaoying; Bian,Meilu; Cong,Xiao; Sun,Aiping; Li,Min; Ma,Li; Chen,Ying; Liu,Jun

doi:10.3892/br.2012.49

March-April 2013 Volume 1 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-April 2013 Volume 1 Issue 2

Full Size Image

Article

Evaluation of a novel real-time fluorescent polymerase chain reaction assay for high-risk human papilloma virus DNA genotypes in cytological cervical screening

Authors:
- Jiaoying Cheng
- Meilu Bian
- Xiao Cong
- Aiping Sun
- Min Li
- Li Ma
- Ying Chen
- Jun Liu
View Affiliations / Copyright

Affiliations: Department of Gynecology and Obstetrics, China-Japan Friendship Hospital, Beijing 100029, P.R. China
Pages: 280-284
|
Published online on: December 17, 2012

https://doi.org/10.3892/br.2012.49
Expand metrics +

Abstract

It has been confirmed that detection of high-risk human papillomavirus (HR HPV) DNA is useful in cervical cancer (CC) screening. Recently, a new real-time fluorescent polymerase chain reaction (PCR) assay was developed to detect HR HPV. This assay can synchronize nucleic acid amplification and testing using specific primers for 13 types of HR HPV genomes, combined with specific TaqMan fluorescent marker probe techniques through the fluorescence automatic PCR instrument. Furthermore, it uses TaqGold™ DNA polymerase, which minimizes the amount of non‑specific amplification and increases the sensitivity of the assay. The aim of this study was to evaluate the analytical and clinical performance of the real‑time fluorescent PCR assay in CC screening, compared to the Qiagen Hybrid Capture® II High‑Risk HPV DNA test® (HC II). In total, 1,252 cervical specimens were collected from women between 19 and 71 years of age. The specimens were examined with three different assays, real‑time fluorescent PCR assay and HC II for HR HPV detection combined with liquid‑based cytology. Women with cytological abnormalities or HR HPV‑positive results underwent colposcopy and cervical biopsy. This study demonstrated good overall agreement between HC II and real‑time fluorescent PCR assay (overall agreement, 92.25%; Cohen's κ=0.814). For the detection of high‑grade cervical intraepithelial neoplasias (CIN) and CC, the sensitivity of HC II and real‑time fluorescent PCR was 94.48 and 92.82%, respectively, and the negative predictive value was 98.85 and 98.54%, respectively. High HR HPV infection rate of the high‑grade CIN and CC group was detected (P<0.05). In conclusion, real-time fluorescent PCR assay provides similar results compared to the HC II test for HR HPV detection and could be used in CC screening in clinic.

View Figures

View References

1	Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsaque X, Shah KV, Snijders PJ and Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papilomavirus types associated with cervical cancer. N Engl J Med. 348:518–527. 2003. View Article : Google Scholar : PubMed/NCBI
2	Ronco G, Biggeri A, Confortini M, et al: Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors. Epidemiol Prev. 36:e1–e72. 2012.(In Italian).
3	Budenholzer B: ACP Journal Club. Adding HPV testing to cytology screening reduced ≥grade 3 cervical intraepithelial neoplasia at 5 years. Ann Intern Med. 157:JC2–JC7. 2012.PubMed/NCBI
4	Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P and Anttila A: Age-specific evaluation of primary human papillomavirus screening vs. conventional cytology in a randomized setting. J Natl Cancer Inst. 101:1612–1623. 2009. View Article : Google Scholar : PubMed/NCBI
5	Davey DD and Zarbo RJ: Human papillomarivus testing - are you ready for a new era in cervical cancer screening? Arch Pathol Lab Med. 127:927–929. 2003.
6	Damasus-Awatai G and Freeman-Wang T: Human papillomavirus and cervical screening. Curr Opin Obstet Gynecol. 15:473–477. 2003. View Article : Google Scholar
7	Petry KU, Menton S, Menton M, et al: Inclusion of HPV testing in routine cervical cancer screening for woman above 29 years in Germany: results for 8,466 patients. Br J Cancer. 88:1570–1577. 2003.PubMed/NCBI
8	Wright TC Jr, Schiffman M, Solomon D, et al: Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 103:304–309. 2004. View Article : Google Scholar
9	Saslow D, Runowicz CD, Solomon D, et al: American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 52:342–362. 2002. View Article : Google Scholar : PubMed/NCBI
10	Sherman ME, Lorincz AT, Scott DR, et al: Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 95:46–52. 2003.PubMed/NCBI
11	Sharma M, Bruni L, Diaz M, Castellsaqué X, de Sanjosé SD, Bosch FX and Kim JJ: Using HPV prevalence to predict cervical cancer incidence. Int J Cancer. Sep 11–2012.(Epub ahead of print). View Article : Google Scholar
12	Castle PE, Schiffman M, Burk RD, et al: Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev. 11:1394–1399. 2002.PubMed/NCBI
13	Poljak M, Marin IJ, Seme K and Vince A: Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol. 25:S89–S97. 2002. View Article : Google Scholar : PubMed/NCBI